Document text
Principal Investigator: Florian Krammer
Organization: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Fiscal Year: 2022
Award: $226,649
Funding agency: National Cancer Institute
PROJECT 1: ABSTRACT
Current information indicates that, in persons without cancer, natural infection with SARS-CoV-2 as well as
vaccination with COVID-19 vaccine candidates induce antibody responses to the spike protein of the virus
which should be protective against future infection. Lung cancer patients who become infected with SARS-
CoV-2 appear to develop severe COVID-19 with a high (35-40%) mortality rate indicating we urgently need to
plan for vaccine trials in this vulnerable population. Currently we have major knowledge gaps to fill in
preparation for such vaccine studies. These include: is there a higher incidence of SARS-CoV-2 in lung cancer
patients compared to the general population? Do lung cancer patients mount a comparable antibody response
in terms of quantity, quality, and longevity to people without lung cancer? Equally important are information in
lung cancer patients on the role of age, gender, smoking status, histology, and types of treatment for lung
cancer on both SARS-CoV-2 infection rate and generation of antibody responses. Through prospective
analyses of lung cancer cases (N= 1,000) and matched controls (N = 1,000) this Project “Characterization of
the Antibody Response to SARS-CoV-2 in Lung Cancer Patients” will provide answers to these important
questions through study of 4 specific aims and the use of our U54 Administrative, Clinical, and Data
Sciences Cores. Aim 1: Characterize the incident, magnitude and functionality of the antibody response to
SARS-CoV-2 in lung cancer patients versus non-lung cancer controls. Aim 2: Compare the longevity of the
antibody response against SARS-CoV-2 in lung cancer patients versus non-lung cancer controls. Aim 3:
Evaluate the impact of patient demographics and cancer-associated clinical factors on the antibody response
in lung cancer patients. And Aim 4: Characterize antibody responses to SARS-CoV-2 vaccination in lung
cancer patients versus non-lung cancer controls. The patient serology specimens will also be studied for viral
neutralizing functionality in collaboration with U54 Project 2. We have assembled a world-class team of lung
cancer clinical translational investigators, serology and virology experts, and patient advocates to address
these key issues. The results of this Project will have a significant impact on lung cancer patient management
during the COVID-19 pandemic, and even greater impact on designing optimal SARS-CoV-2 vaccination
regimens for lung cancer patients.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><Address><Advocate><Age><Antibodies><Antibody Response><Assay><Binding><Bioassay><Biologic Assays><Biological Assay><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 antibody><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 vaccination><COVID-19 vaccine><COVID-19 virus><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 public health crisis><COVID19 vaccination><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cancer Control><Cancer Control Science><Cancer Patient><Cancer Treatment><Cancers><Cell Body><Cells><Clinical><Clinical Sciences><Clinical Trials><CoV-2><CoV2><Collaborations><Complement><Complement Proteins><Coronaviridae><Coronavirus><Cricetinae><Data Science Core><Data Science Resource Core><Demographic Impact><Development><Epithelial Cells><Ethnic Origin><Ethnicity><Fc Receptor><Future><Gender><General Population><General Public><Generations><Glycoproteins><Hamsters><Hamsters Mammals><Histology><Immune><Immune response><Immunes><Immunity><Immunological response><Incidence><Individual><Infection><Kinetics><Knowledge><Length of Life><Longevity><Lung><Lung Respiratory System><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Lung><Malignant neoplasm of lung><Mediating><Modeling><Molecular Interaction><Patients><Persons><Policies><Population><Predisposition><Preparation><Pulmonary Cancer><Pulmonary malignant Neoplasm><Race><Racial Group><Racial Stocks><Receptor Protein><Regimen><Research Specimen><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 antibody><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 vaccination><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 antibody><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Serology><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Smoking History><Smoking Status><Specimen><Statistical Data Analyses><Statistical Data Analysis><Statistical Data Interpretation><Susceptibility><Testing><Vaccinated><Vaccination><Vaccines><Viral><Viral Antigens><Viral Gene Products><Viral Gene Proteins><Viral Proteins><Virus><Vulnerable Populations><Work><Wuhan coronavirus><ages><anti-cancer therapy><antibody against COVID-19><antibody against SARS-CoV-2><antibody against SARS-CoV2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody receptor><antibody to COVID-19><antibody to SARS-CoV-2><antibody to SARS-CoV2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><anticancer therapy><base><block viral entry><cancer therapy><cancer-directed therapy><case control><case-controlled><co-morbid><co-morbidity><comorbidity><comparative><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 antibody><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 vaccination><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><cytokine><demographics><design><designing><developmental><hCoV19><host response><immune system response><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><infection rate><inhibit viral entry><insight><inter-individual variability><inter-individual variation><interindividual variability><interindividual variation><life span><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><lifespan><lung cancer><lung cancer cell><malignancy><mortality><nCoV2><neoplasm/cancer><neutralizing antibody><pack years><patient response><patient specific response><power analysis><prospective><protective efficacy><pulmonary><rate of infection><receptor><response><responsive patient><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><seropositive><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><social role><statistical analysis><trait><translational investigator><translational researcher><translational scientist><vaccinate against COVID-19><vaccinate against COVID19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccination against COVID-19><vaccination against COVID19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccination study><vaccination trial><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidate><vaccine for novel coronavirus><vaccine response><vaccine responsiveness><vaccine study><vaccine trial><vaccine-induced response><viral entry blocker><viral entry inhibitor><virology><virus antigen><virus protein><vulnerable group><vulnerable people>